# Pizarra — PT-pseudo_394e0b8dbeeb (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_394e0b8dbeeb
Task: 1

Encounter: Urology - outpatient on 04 Jan 2025.
Referrer: Dr. E. Mulder (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 71-year-old male
  - PSA: 9.2 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.17 ng/mL²
  - PSA velocity: 1.1 ng/mL/yr
  - Prior PSA: 10.1 ng/mL
  - Prostate volume: 53.0 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.78939086 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypercholesterolaemia, Coronary artery disease, Obesity (BMI >30), Benign prostatic hyperplasia
  - Problem list / PMHx: Hypercholesterolaemia, Coronary artery disease, Obesity (BMI >30), Benign prostatic hyperplasia
  - Current medication: atorvastatin, simvastatin, rosuvastatin, aspirin 80 mg, metoprolol, tamsulosin
  - Allergies: NKA
  - Additional notes: PSA 9.2 ng/mL. PI-RADS 4. PSAD 0.17. Prostate volume 53 mL. DRE nodus. csPCa 0.79.

Vitals: weight 93 kg, height 164 cm, BMI 34.6, BP 114/71 mmHg, HR 70 bpm. Smoking: Current smoker (45 pack-yr).

Chief complaint: Elevated PSA progression alongside a newly identified PI-RADS 4 lesion on multiparametric MRI has necessitated specialist re-assessment.

History: Mr X, a 71-year-old harbour pilot (semi-retired), entered initial evaluation in early 2023 following an incidental PSA elevation. Lower urinary tract symptoms remain mild and are currently managed with tamsulosin, yielding an IPSS score of 7. He reports no haematuria or acute urinary retention. Cardiovascular comorbidities encompass coronary artery disease and hypercholesterolaemia, managed through a regimen of atorvastatin, simvastatin, rosuvastatin, aspirin 80 mg, and metoprolol. He is a Current smoker (45 pack-yr) but maintains physical activity by cycling roughly 30 kilometres three times weekly. Obesity (BMI >30) is present. He remains married and lives with his partner. An adult daughter handles his medical correspondence upon request. Aside from the urological investigations, he experiences stable bilateral knee discomfort stemming from years of deck work and recently visited a podiatrist for routine nail care. No systemic symptoms or unexplained weight loss are reported.

Physical examination: DRE — prostate: asymmetrically enlarged, firm texture, discrete nodule palpable in the right mid-gland. General examination remains unremarkable, with stable vital signs and no evidence of palpable lymphadenopathy or abdominal masses.

Patient info: harbour pilot (semi-retired); Married; Lives with partner.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 8 units / week; exercise Cycling 3x/week, ~30 km; IPSS score: 7/35 (mild LUTS).

Recent other appointments: Podiatry — routine foot care.
Admin: Daughter manages communication; CC on letters with patient consent.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.70 +/- 0.20   (95% CI 0.25-0.98)

Where the uncertainty comes from:
  - aleatoric  dA = 0.18  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.09  (few labelled cases resemble this one)
  - 3.6 effective neighbours out of 10; 5 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'supports': A +/- dA does not cross 0.5, but A +/- 1.96*dA does. There is a direction, not a conclusion. Measured accuracy in this tier: 0.67. Treat it as a weighted vote, not as a decision.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=1.0, psa=9.2, age=71.0, psad=0.17, dre_ord=1.0, vol=53.0, n_pmhx=4.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior negative biopsy.

CRITERION VERDICT: BIOPSY.

The criterion: Re-biopsy (targeted) when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for a PI-RADS 3 or lower picture that has not changed.

In the labelled cohort this criterion matched the reading urologist in 16 of the 18 cases with a prior negative biopsy.

Track record of this criterion on the labelled cohort: 16 of 18 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only considered the visible panel data (PI-RADS 4, PSA 9.2, age 71, PSA density 0.17, DRE nodule, volume 53.0 mL, and 4 PMHx). It failed to incorporate the PSA velocity (1.1 ng/mL/yr), the prior PSA (10.1 ng/mL), and the specific csPCa predicted probability (0.78939086).

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy based on a high probability (0.70), but the guideline criterion is based on a specific PI-RADS 4-5 lesion, which is present. However, the prior does not account for the context of a prior negative biopsy, which the protocol expert noted is a key factor. The prior's uncertainty (dA = 0.18) suggests the nearest cases disagree, meaning the prior might be overconfident given the complexity of the prior negative status.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
PSA history - trend / velocity beyond the headline value
previous GP / urology notes - context regarding the prior negative biopsy
laboratory panel - full panel
previous notes - context regarding the prior negative biopsy

GUIDELINE ANCHOR
The guideline states that a repeat biopsy is mandated when an mpMRI shows a PI-RADS 4-5 lesion, and it constrains the decision by requiring a specific finding from a retrieved document.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_394e0b8dbeeb", "radiology_report": "Subject: Multiparametric MRI Prostate | Date: 20 December 2024 | Institution: Jeroen Bosch Ziekenhuis ('s-Hertogenbosch)\nClinical Context: 71-year-old male presenting with a PSA trajectory of 9.2 ng/mL and a previously documented negative biopsy bucket.\n\nFINDINGS:\nThe gland measures 53.0 mL in total volume. T2-weighted sequences identify a 12 mm hypointense focus within the right mid-gland, reaching toward the peripheral zone. Margins appear irregular with architectural disruption. Diffusion-weighted imaging demonstrates significant restriction paired with low ADC values, indicating increased cellularity. Dynamic contrast enhancement is early and focal compared to adjacent tissue. Seminal vesicles appear normal. There is no evidence of extraprostatic extension or pelvic lymphadenopathy.\n\nIMPRESSION:\nPI-RADS 4 lesion in the right mid-gland peripheral zone.\nProstate volume 53.0 mL yielding a PSA density of 0.17 ng/mL/mL.\ncsPCa predicted probability 0.78939086."}
get_psa_trend
{"case_id": "PT-pseudo_394e0b8dbeeb", "psa_trend": [{"date": "Apr 2023", "val": 7.0}, {"date": "Nov 2023", "val": 7.9}, {"date": "Jun 2024", "val": 6.5}, {"date": "Jan 2025", "val": 9.2}]}
get_previous_notes
{"case_id": "PT-pseudo_394e0b8dbeeb", "previous_notes": [{"date": "15 Jan 2023", "author": "Dr. E. Mulder (GP)", "text": "Initial laboratory workup in April 2023 flagged a PSA elevation of 6.1 ng/mL. The individual noted mild urinary hesitancy, though acute retention and haematuria were absent. Because of his age and the first elevation, clinicians arranged a follow-up PSA test six months later and initiated a urology referral for baseline evaluation."}, {"date": "06 Sep 2024", "author": "Dr. E. Mulder (GP)", "text": "Subsequent laboratory data collected in June 2024 showed a further rise to 10.1 ng/mL, prompting a repeat multiparametric MRI that located a suspicious focus. In light of the earlier negative biopsy, the steady upward PSA trend, and the present imaging results, specialist input was requested. The case was forwarded to the urology outpatient department for clinical re-assessment and to review targeted sampling options."}]}
get_lab_results
{"case_id": "PT-pseudo_394e0b8dbeeb", "laboratory_results": [{"name": "PSA", "val": "9.2 ng/mL", "date": "21 Nov 2024", "flag": "H"}, {"name": "Free PSA", "val": "1.44 ng/mL", "date": "21 Nov 2024", "flag": ""}, {"name": "%Free PSA", "val": "16%", "date": "21 Nov 2024", "flag": "L"}, {"name": "Haemoglobin", "val": "15.0 g/dL", "date": "21 Nov 2024", "flag": ""}, {"name": "WBC", "val": "7.5 x10^9/L", "date": "21 Nov 2024", "flag": ""}, {"name": "Platelets", "val": "310 x10^9/L", "date": "21 Nov 2024", "flag": ""}, {"name": "Creatinine", "val": "107 umol/L", "date": "21 Nov 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "21 Nov 2024", "flag": ""}, {"name": "Testosterone", "val": "8.5 nmol/L", "date": "21 Nov 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "63 U/L", "date": "21 Nov 2024", "flag": ""}, {"name": "LDH", "val": "160 U/L", "date": "21 Nov 2024", "flag": ""}]}

NOT RETRIEVED
The family history of prostate cancer was not retrieved, which is not required for this decision.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- mpMRI report: PI-RADS 4 lesion in the right mid-gland peripheral zone.
- PSA trend: Rising from 6.5 ng/mL (Jun 2024) to 9.2 ng/mL (Jan 2025), with a velocity of 1.1 ng/mL/yr.
- Previous notes: Context indicates a prior negative biopsy and a steady upward PSA trend prompting re-assessment.

AGAINST sampling this patient now:
- Previous notes: Prior biopsy was negative.

WHERE THIS LEANS
The evidence strongly supports re-biopsy based on the PI-RADS 4 finding and the rising PSA trend, aligning with the EXPERT-PROTOCOL guideline criterion. This confirms the statistical prior's suggestion.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The guideline criterion mandates biopsy due to the PI-RADS 4 lesion, which is decisive, and the prior negative biopsy status is also decisive. This decision is strongly supported by the rising PSA trend (1.1 ng/mL/yr) and the specific finding in the retrieved mpMRI report. The statistical prior suggested biopsy, and the evidence converges on this recommendation.

Variables that carried weight: bx=decisive, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
